Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis (RELIEF-SCC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04614610|
Recruitment Status : Recruiting
First Posted : November 4, 2020
Last Update Posted : January 22, 2021
|Condition or disease||Intervention/treatment||Phase|
|Sickle Cell Disease Sickle Cell Crisis Pain, Acute||Drug: Lidocaine Iv Drug: Placebo||Phase 2|
Pain is the most frequent reason for emergency department visits in the United States, especially for those patients with sickle cell disease (SCD). Painful vaso-occlusive events frequently require admission to the hospital despite opioid therapy, which is the mainstay of treatment for moderate to severe pain in SCD. Achieving adequate pain control with escalating doses of opioid analgesics may be difficult due to tolerance, physical dependence, and side effects. Common side effects include pruritus, nausea and vomiting, constipation, urinary retention, sedation, and respiratory depression. With the recent focus on the opiate crisis there has been a push towards the use of alternative to opiates (ALTO) for a variety of pain syndromes.
Lidocaine is a class 1b sodium channel blocking agent that is typically used as an anti-arrhythmic and local anesthetic. This medication also has potent anti-inflammatory, anti-hyperalgesic, and gastrointestinal pro-peristaltic properties. Lidocaine may be useful as an adjunct to opioids in response to a painful sickle cell crisis. Intravenous (IV) lidocaine infusion has previously shown benefit in neuropathic pain, renal colic, and peri-operative pain. No prospective studies have evaluated lidocaine for SCD pain thus far.
A previous retrospective study evaluated lidocaine infusion as adjuvant therapy to patients with SCD. Eleven patients were given a total of 15 IV lidocaine trials. Investigators found clinical improvement in pain score from pre-lidocaine challenge to 24 hours post (defined as a >20% reduction in pain scores) in 53.3% (8 of 15) of patients. Of the 8 clinically successful trials, the mean reduction in morphine dose equivalents (MDE) from 24 hours pre to 24 hours post lidocaine was 32.2%. Two patients experienced disorientation and dizziness. The authors concluded that lidocaine was able to provide pain relief and reduce the amount of morphine necessary during SCD vaso-occlusive crisis and that prospective studies are needed to determine its true efficacy, dosing, and tolerability.
A prospective, single-arm, phase II trial evaluated lidocaine 5% patches for neuropathic pain and pain related to vaso-occlusive sickle cell crises in children ages 6 to 21 years old. Patches were applied to the painful area for 12 hours a day. The primary endpoint was the proportion of inpatients with significant pain relief defined as a decrease of at least 2 points on the visual analog pain scale (VAS, from 0-10) measured at 12 hours after patch placement over two consecutive days. The use of additional treatments such as antiepileptics and opioids were allowed and their usage was documented. The primary outcome of VAS improvement of >2 over 2 consecutive days was observed in 48.6% of evaluated patients (19/39). Transdermal lidocaine was tolerated well with only 3 minor adverse events reported (two localized skin reactions and one generalized skin eruption) and no serious adverse events.
The theoretical benefits along with the two previously discussed studies provide evidence to further investigate the use of lidocaine in SCD pain. Studies are needed to know whether lidocaine may be able to benefit alleviate pain quicker and minimize need for opiates similarly to its use in renal colic. This prospective trial aims to evaluate whether lidocaine can decrease the opiate needs during a SCD crisis while providing adequate pain relief and tolerability.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Patients presenting to the emergency department for an acute sickle cell crisis who are refractory to one dose of intravenous opiate therapy will be randomized to either lidocaine 1.5mg/kg (max: 200mg) or matching dextrose placebo along with either morphine 0.1-0.15mg/kg IV or hydromorphone 0.01-0.02mg/kg IV.|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Masking Description:||Lidocaine or placebo will be dispensed from the pharmacy in identical bags labeled "Lidocaine (x)mg or Placebo". The pharmacy will maintain randomization and blinding until the end of the study.|
|Official Title:||Randomized Trial Evaluating Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis - RELIEF-SCC|
|Actual Study Start Date :||November 3, 2020|
|Estimated Primary Completion Date :||November 2, 2021|
|Estimated Study Completion Date :||February 1, 2022|
Active Comparator: Lidocaine
Lidocaine 1.5mg/kg (Max: 200mg) in dextrose 5% 100mL over 10 minutes along with either morphine 0.1-0.15mg/kg IV OR hydromorphone 0.01-0.02mg/kg IV.
Drug: Lidocaine Iv
Lidocaine 1.5mg/kg (Max dose: 200mg) in Dextrose 5% 100mL over 10 minutes
Placebo Comparator: Placebo
Dextrose 5% 100mL (placebo) over 10 minutes along with either morphine 0.1-0.15mg/kg IV OR hydromorphone 0.01-0.02mg/kg IV.
Dextrose 5% 100mL over 10 minutes
- Change in pain at 30 minutes [ Time Frame: from pre-lidocaine infusion to 30 minutes post-infusion ]Change of visual analog pain scale (VAS, 0-10) at 30 minutes post-infusion of lidocaine or placebo.
- Total opiate dosage received [ Time Frame: from presentation to the Emergency department (ED) until patient disposition (up to 12 hours) ]Total morphine mg equivalents (MME) of opiate received normalized to patient's bodyweight during their ED stay.
- % Patients requiring additional opiate administration [ Time Frame: from presentation to the Emergency department (ED) until patient disposition (up to 12 hours) ]Percentage of patients requiring an additional opiate after the lidocaine vs. placebo.
- Time to next opiate administered [ Time Frame: from administration of lidocaine infusion until patient disposition (up to 12 hours) or next opiate administered ]Time (minutes) until next opiate is administered after lidocaine vs. placebo.
- Total MME post-lidocaine up to 12 hours [ Time Frame: 12 hours post-lidocaine or placebo infusion. ]Total MME needed after lidocaine vs placebo up to 12 hours
- Percentage of patients discharged from ED [ Time Frame: from presentation to the Emergency department (ED) until patient disposition (up to 12 hours) ]Percentage of patients discharged from the ED.
- Percentage of patients receiving a >20% reduction in pain scale [ Time Frame: from presentation to the Emergency department (ED) until patient disposition (up to 12 hours) ]Percentage of patients receiving a >20% reduction in pain scale based on the VAS (0-10).
- Change in visual analog pain scale (VAS, 0-10 with 10 being the most pain) at 60 and 90 minutes [ Time Frame: 60 and 90 minutes ]Change in VAS at 60 and 90 minutes post-infusion.
- Number of adverse effects of treatment [ Time Frame: from presentation to the Emergency department (ED) until patient disposition (up to 12 hours) ]Reported adverse effects during study treatment period
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04614610
|Contact: Andrew V Vassallo, PharmD||732-557-8070||Andrew.Vassallo@rwjbh.org|
|Contact: Kristine Sobolewski, PharmDfirstname.lastname@example.org|
|United States, New Jersey|
|Saint Barnabas Medical Center||Recruiting|
|Livingston, New Jersey, United States, 07039|
|Contact: Kristine Sobolewski, PharmD Kristine.Sobolewski@rwjbh.org|
|Monmouth Medical Center||Not yet recruiting|
|Long Branch, New Jersey, United States, 07740|
|Contact: Harisios Tjionas, MD email@example.com|
|Contact: Nicole Keegan, DNP Nicole.Keegan@rwjbh.org|
|Newark Beth Israel Medical Center||Not yet recruiting|
|Newark, New Jersey, United States, 07112|
|Contact: Shreni Zinzuwadia, MD firstname.lastname@example.org|
|Contact: Patrick Hinfey, MD Patrick.Hinfey@rwjbh.org|
|Principal Investigator:||Shreni Zinzuwadia, MD||Newark Beth Israel|